Host responses to infection with human papillomavirus

Current Problems in Dermatology (Switzerland)

Volumn 45, Issue , 2014, Pages 58-74

  Stanley, Margaret A ^a   Sterling, Jane C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DEDICATOR OF CYTOKINESIS 8 PROTEIN; INTERFERON; PEPTIDES AND PROTEINS; PROTEIN E6; PROTEIN E7; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE RESPONSE; DENDRITIC CELL; EFFECTOR CELL; EPIDERMODYSPLASIA VERRUCIFORMIS; EPISOME; FANCONI ANEMIA; GENE MUTATION; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINE LYMPHANGIECTASIA; KERATINOCYTE; LYMPHOCYTOPENIA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS LIKE AGENT; WART VIRUS; HOST PATHOGEN INTERACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PAPILLOMA VIRUS; PHYSIOLOGY;

HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNOCOMPROMISED HOST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84921454183     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000355964     Document Type: Article

References (88)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79
2. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S: Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(suppl 5):F12-F23
3. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M: Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012; 13: 607-615
4. Lacey CJ, Lowndes CM, Shah KV: Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(suppl 3): 35-41
5. Rubben A, Krones R, Schwetschenau B, Grussendorf-Conen EI: Common warts from immunocompetent patients show the same distribution of human papillomavirus types as common warts from immunocompromised patients. Br J Dermatol 1993; 128: 264-270
6. Weissenborn S, Neale RE, Waterboer T, Abeni D, Bavinck JN, Green AC, Harwood CA, Euvrard S, Feltkamp MC, de Koning MN, Naldi L, Quint WG, Tessari G, Proby CM, Wieland U, Pfister H, group E-H-U-C: Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. Med Microbiol Immunol 2012; 201: 117-125
7. Dell'Oste V, Azzimonti B, De Andrea M, Mondini M, Zavattaro E, Leigheb G, Weissenborn SJ, Pfister H, Michael KM, Waterboer T, Pawlita M, Amantea A, Landolfo S, Gariglio M: High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol 2009; 129: 1026-1034
8. Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, Puck J, Roifman C, Seger R, Geha RS, International Union of Immunological Societies Primary Immunodeficiency Diseases Classification C: Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006; 117: 883-896
9. Laffort C, Le Deist F, Favre M, Caillat-Zucman S, Radford-Weiss I, Debre M, Fraitag S, Blanche S, Cavazzana-Calvo M, de Saint Basile G, de Villartay JP, Giliani S, Orth G, Casanova JL, Bodemer C, Fischer A: Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gamma cytokine receptor subunit or JAK-3 deficiency. Lancet 2004; 363: 2051-2054
10. Zhang Q, Su HC: Hyperimmunoglobulin E syndromes in pediatrics. Curr Opin Pediatr 2011; 23: 653-658
11. Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, Frucht DM, Vinh DC, Auth RD, Freeman AF, Olivier KN, Uzel G, Zerbe CS, Spalding C, Pittaluga S, Raffeld M, Kuhns DB, Ding L, Paulson ML, Marciano BE, Gea-Banacloche JC, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM: Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118: 2653-2655
12. Vu J, Wallace GR, Singh R, Diwan H, Prieto V, Rady P, Tyring S, Duvic M: Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol 2007; 8: 307-310
13. Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M: Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008; 205: 35-42
14. Crequer A, Picard C, Pedergnana V, Lim A, Zhang SY, Abel L, Majewski S, Casanova JL, Jablonska S, Orth G, Jouanguy E: EVER2 deficiency is associated with mild T-cell abnormalities. J Clin Immunol 2013; 33: 14-21
15. Tarzi MD, Jenner M, Hattotuwa K, Faruqi AZ, Diaz GA, Longhurst HJ: Sporadic case of warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome. J Allergy Clin Immunol 2005; 116: 1101-1105
16. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, François F, Klotman ME, Diaz GA: Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34: 70-74
17. Handisurya A, Schellenbacher C, Reininger B, Koszik F, Vyhnanek P, Heitger A, Kirnbauer R, Forster-Waldl E: A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine 2010; 28: 4837-4841
18. Kreuter A, Hochdorfer B, Brockmeyer NH, Altmeyer P, Pfister H, Wieland U, Competence Network HA: A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Arch Dermatol 2008; 144: 366-372
19. Mansour S, Connell F, Steward C, Ostergaard P, Brice G, Smithson S, Lunt P, Jeffery S, Dokal I, Vulliamy T, Gibson B, Hodgson S, Cottrell S, Kiely L, Tinworth L, Kalidas K, Mufti G, Cornish J, Keenan R, Mortimer P, Murday V, Lymphoedema Research C: Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases. Am J Med Genet A 2010; 152A:2287-2296
20. Vignes S, Bellanger J: Primary intestinal lymphangiectasia (Waldmann's disease). Orphanet J Rare Dis 2008; 3: 5
21. Ross IN, Chesner I, Thompson RA, Parker RG, Asquith P: Cutaneous viral infection as a presentation of intestinal lymphangiectasia. Br J Dermatol 1982; 107: 357-363
22. Fischer LA, Norgaard A, Permin H, Ryder LP, Marquart H, Svejgaard A, Zachariae C: Multiple flat warts associated with idiopathic CD4-positive T lymphocytopenia. J Am Acad Dermatol 2008; 58(suppl):S37-S38
23. Stetson CL, Rapini RP, Tyring SK, Kimbrough RC: CD4 T lymphocytopenia with disseminated HPV. J Cutan Pathol 2002; 29: 502-505
24. Ladoyanni E, North J, Tan CY: Idiopathic CD4 Tcell lymphocytopaenia associated with recalcitrant viral warts and squamous malignancy. Acta Derm Venereol 2007; 87: 76-77
25. Purnell D, Ilchyshyn A, Jenkins D, Salim A, Seth R, Snead D: Isolated human papillomavirus 18-positive extragenital bowenoid papulosis and idiopathic CD4 lymphocytopenia. Br J Dermatol 2001; 144: 619-621
26. Tomson N, Sterling J, Miller R, Wilson C, Baldwin P: Vulval and perianal intraepithelial neoplasia: response to chemoradiotherapy in a woman with idiopathic CD4 lymphocytopenia. Clin Exp Dermatol 2012; 37: 865-868
27. Fairbanks LD, Simmonds HA, Webster AD, Shovlin CL, Hughes JM: Adenosine deaminase (ADA) deficiency as the unexpected cause of CD4 T-lymphocytopenia in two HIV-negative adult female siblings. Adv Exp Med Biol 1994; 370: 471-474
28. Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, Huvos AG, Giampietro P, Levran O, Pujara K, Diotti R, Carlson D, Huryn LA, Auerbach AD, Singh B: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003; 95: 1718-1721
29. Leiding JW, Holland SM: Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012; 130: 1030-1048
30. Gassenmaier A, Fuchs P, Schell H, Pfister H: Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch Dermatol Res 1986; 278: 219-223
31. Kohler A, Meyer T, Stockfleth E, Nindl I: High viral load of human wart-associated papillomaviruses (PV) but not beta-PV in cutaneous warts independent of immunosuppression. Br J Dermatol 2009; 161: 528-535
32. Purdie KJ, Surentheran T, Sterling JC, Bell L, Mc-Gregor JM, Proby CM, Harwood CA, Breuer J: Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol 2005; 125: 98-107
33. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T: Human papillomaviruses in transplantassociated skin cancers. Dermatol Surg 2004; 30: 604-609
34. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu Uvin S, Duerr A, Greenblatt RM, Klein RS, Massad S, Minkoff H, Muderspach L, Palefsky J, Piessens E, Schuman P, Watts H, Shah KV: The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002; 29: 427-435
35. Meys R, Gotch FM, Bunker CB: Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease? Br J Dermatol 2010; 162: 6-11
36. Lei YJ, Gao C, Wang C, Han J, Chen JM, Xiang GC, Shi Q, Jiang HY, Zhou W, An R, Dong CF, Yuan YK, Dong XP: Molecular epidemiological study on prevalence of human papillomaviruses in patients with common warts in Beijing area. Biomedical and environmental sciences. Biomed Environ Sci 2009; 22: 55-61
37. Alisjahbana B, Dinata R, Sutedja E, Suryahudaya I, Soedjana H, Hidajat NN, Soetikno RD, Oktaliansah E, Deng A, Rady P, Tyring S, Gaspari AA: Disfiguring generalized verrucosis in an Indonesian man with idiopathic CD4 lymphopenia. Arch Dermatol 2010; 146: 69-73
38. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA: The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(suppl 5): F55-F70
39. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Gough GW, Stanley MA: Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999; 265: 365-374
40. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA: Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199: 805-814
41. Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117(suppl): S5-S10
42. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ: Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-691
43. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826
44. Nasu K, Narahara H: Pattern recognition via the Toll-like receptor system in the human female genital tract. Mediators Inflamm 2010; 2010: 976024
45. Loo YM, Gale M, Jr: Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692
46. Kawai T, Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650
47. Taylor KE, Mossman KL: Recent advances in understanding viral evasion of type I interferon. Immunology 2013; 138: 190-197
48. Diamond MS, Farzan M: The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013; 13: 46-57
49. Antonsson A, Payne E, Hengst K, McMillan NA: The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res 2006; 26: 455-461
50. Arany I, Grattendick KJ, Whitehead WE, Ember IA, Tyring SK: A functional interferon regulatory factor-(IRF-1)-binding site in the upstream regulatory region (URR) of human papillomavirus type 16. Virology 2003; 310: 280-286
51. Perea SE, Massimi P, Banks L: Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int J Mol Med 2000; 5: 661-666
52. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS: Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 2002; 179: 205-212
53. Ronco LV, Karpova AY, Vidal M, Howley PM: Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998; 12: 2061-2072
54. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, Matlashewski GJ, Koromilas AE: The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999; 18: 5727-5737
55. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD: Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001; 75: 4283-4296
56. Karstensen B, Poppelreuther S, Bonin M, Walter M, Iftner T, Stubenrauch F: Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. Virology 2006; 353: 200-209
57. Chang YE, Laimins LA: Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000; 74: 4174-4182
58. Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T, Stubenrauch F: High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 2011; 85: 11372-11380
59. Wentzensen N, Vinokurova S, von Knebel Doeberitz M: Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004; 64: 3878-3884
60. Pett M, Coleman N: Integration of high-risk human papillomavirus: A key event in cervical carcinogenesis? J Pathol 2007; 212: 356-367
61. Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA, Coleman N: Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res 2002; 62: 6959-6965
62. Pett MR, Herdman MT, Palmer RD, Yeo GS, Shivji MK, Stanley MA, Coleman N: Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci US A 2006; 103: 3822-3827
63. Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang XY, Stanley MA, Coleman N: Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 2006; 27: 2341-2353
64. Hebner C, Beglin M, Laimins LA: Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. J Virol 2007; 81: 12740-12747
65. Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-265
66. Arend WP, Palmer G, Gabay C: IL-1, IL-18, and IL-families of cytokines. Immunol Rev 2008; 223: 20-38
67. Black AP, Ardern-Jones MR, Kasprowicz V, Bowness P, Jones L, Bailey AS, Ogg GS: Human keratinocyte induction of rapid effector function in antigenspecific memory CD4 and CD8 T cells. Eur J Immunol 2007; 37: 1485-1493
68. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, van Ommen GJ, Melief CJ, van der Burg SH, Boer JM: Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011; 6:e17848
69. Fausch SC, Da Silva DM, Rudolf MP, Kast WM: Human papillomavirus virus-like particles do not activate Langerhans cells: A possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169: 3242-3249
70. Da Silva DM, Fausch SC, Verbeek JS, Kast WM: Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 2007; 178: 7587-7597
71. Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Backstrom BT, Doorbar J, Hibma M: Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003; 77: 8378-8385
72. Leong CM, Doorbar J, Nindl I, Yoon HS, Hibma MH: Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types. Br J Dermatol 2010; 163: 1253-1263
73. Van Seters M, Beckmann I, Heijmans-Antonissen C, van Beurden M, Ewing PC, Zijlstra FJ, Helmerhorst TJ, KleinJan A: Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. Cancer Res 2008; 68: 6617-6622
74. Guess JC, McCance DJ: Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 2005; 79: 14852-14862
75. Igyártó BZ, Kaplan DH: Antigen presentation by Langerhans cells. Current opinion in immunology 2013; 25: 115-119
76. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, Wasan PS, Wang XN, Malinarich F, Malleret B, Larbi A, Tan P, Zhao H, Poidinger M, Pagan S, Cookson S, Dickinson R, Dimmick I, Jarrett RF, Renia L, Tam J, Song C, Connolly J, Chan JK, Gehring A, Bertoletti A, Collin M, Ginhoux F: Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103 nonlymphoid dendritic cells. Immunity 2012; 37: 60-73
77. Nakayama Y, Asagoe K, Yamauchi A, Yamamoto T, Shirafuji Y, Morizane S, Nakanishi G, Iwatsuki K: Dendritic cell subsets and immunological milieu in inflammatory human papilloma virus-related skin lesions. J Dermatol Sci 2011; 63: 173-183
78. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J: Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30(suppl 5): F24-F33
79. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, Stanley MA: Regression of canine oral papillomas is associated with infiltration of CD4 and CD8 lymphocytes. Virology 2001; 283: 31-39
80. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor Robinson D, Stanley MA: Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102: 768-774
81. De Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R: Frequent detection of human papillomavirus. E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-479
82. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH: Frequent display of human papillomavirus type 16 E6-specific memory Thelper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63: 636-641
83. Woo YL, van den Hende M, Sterling JC, Coleman N, Crawford RA, Kwappenberg KM, Stanley MA, van der Burg SH: A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6-and E7-specific T-cell responses. Int J Cancer 2010; 126: 133-141
84. Jain S, Moore RA, Anderson DM, Gough GW, Stanley MA: Cell-mediated immune responses to COPV early proteins. Virology 2006; 356: 23-34
85. McKenzie J, King A, Hare J, Fulford T, Wilson B, Stanley M: Immunocytochemical characterization of large granular lymphocytes in normal cervix and HPV associated disease. J Pathol 1991; 165: 75-80
86. Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D, Kos F, Teague J, Jiang Y, Barat NC, Jungbluth AA: Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010; 185: 7107-7114
87. Schiller JT, Castellsague X, Garland SM: A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123-F138
88. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-492.